CAS
ITCI

Coppell Advisory Solutions’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Coppell Advisory Solutions’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-282
Closed -$23.5K – 1981
2024
Q4 		$23.5K Buy
+282
New +$23.2K ﹤0.01% 814
2023
Q4 		$22.1K Sell
309
-582
-65% -$33.5K ﹤0.01% 700
2023
Q3 		$47.2K Buy
+891
New +$51.9K 0.02% 316
2023
Q1 		– Sell
-891
Closed -$47.2K – 1136
2022
Q4 		$47.2K Buy
+891
New +$44.7K 0.02% 319

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Coppell Advisory Solutions's ITCI Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 282 shares — an estimated $23.5K sold.

Coppell Advisory Solutions first reported a position in ITCI in Q4 2022 and held it in 4 quarters. The position peaked at $47.2K in Q3 2023. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 282 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $23.5K.
  • Coppell Advisory Solutions first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 4 quarters.
  • Coppell Advisory Solutions's Intra-Cellular Therapies Inc. position peaked at $47.2K in Q3 2023.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.